Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Brian Rosenzweig is a partner in the firm’s New York office and a member of the Corporate Practice Group. He practices corporate and securities law, with an emphasis on domestic and international capital-raising transactions and SEC reporting and compliance. His practice predominantly involves capital markets transactions, including initial public offerings, follow-on equity offerings and high-yield debt offerings, involving domestic and foreign private issuers in the life sciences, technology, and financial services industries. He also regularly advises boards and management on executive compensation disclosure and other securities law issues, corporate governance issues, and general corporate matters.

  • Representing Uber Technologies, Inc. in connection with its US IPO on the New York Stock Exchange.
  • Representing the underwriters in the US IPO of Trevi Therapeutics, Inc., clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions.
  • Represented the underwriters in the US IPO and multiple follow-on offerings of ordinary shares of UroGen Pharma Ltd., an Israeli biopharmaceutical company focused on non-surgical treatments in uro-oncology.
  • Represented the underwriters in the US IPO of American Depositary Shares of Nabriva Therapeutics AG, an Austria-based biopharmaceutical company focused on developing a new class of antibiotics.
  • Represented the underwriters in the US IPO and a follow-on offering of ordinary shares of Affimed N.V., a German-based biotechnology company focused on immuno-oncology.
  • Represented Lombard Medical, Inc., a UK-based medical device company focused on endovascular stent-grafts for the repair of aortic aneurysms, in its US IPO of ordinary shares.
  • Represented the underwriters in the US IPO and a follow-on offering of ordinary shares of uniQure N.V., an Amsterdam-based gene therapy company.
  • Represented a Swedish issuer in connection with the 144A/Reg S offering of senior notes and PIK notes to refinance high yield and PIK bridge loans incurred in connection with the acquisition of Polkomtel, a Polish telecommunications provider.
  • Represented Darwin Professional Underwriters Inc., a specialty insurance group focused on the professional liability insurance market, in its US IPO.
  • Represented the underwriters in two publicly registered offerings of high yield notes for HealthSouth Corporation, a provider of inpatient rehabilitative healthcare services.
  • Represented the underwriters in two public offerings of common stock of Bruker Corporation, a biotechnology company focused on analytical tools based on mass spectrometry and X-ray devices.

Memberships and Affiliations

  • Society of Corporate Secretaries and Governance Professionals
  • Chambers USA, Capital Markets: Debt & Equity (2017, 2018, 2019)
  • Legal 500 US, Capital Markets: Equity Offerings (2016)
  • New York Super Lawyers “Rising Star” (2014, 2015, 2016, 2017)